Aztreonam Lysine for Pseudomonas Infection Eradication Study (ALPINE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01375049
First received: June 15, 2011
Last updated: July 7, 2014
Last verified: July 2014

June 15, 2011
July 7, 2014
August 2011
May 2013   (final data collection date for primary outcome measure)
  • Percentage of Participants With PA-negative Cultures at All Time Points After Cessation of Active Treatment (Evaluable Analysis Set) [ Time Frame: Day 28 to Day 196 ] [ Designated as safety issue: No ]
    The percentage of participants with PA-negative cultures at all time points after cessation of active treatment at Day 28 (assessed at Days 56, 112, and 196) was summarized for the Evaluable Analysis Set.
  • Percentage of Participants With PA-negative Cultures at All Time Points After Cessation of Active Treatment (Sensitivity Analysis Set) [ Time Frame: Day 28 to Day 196 ] [ Designated as safety issue: No ]
    The percentage of participants with PA-negative cultures at all time points after cessation of active treatment at Day 28 (assessed at Days 56, 112, and 196) was summarized for the Sensitivity Analysis Set.
Proportion of patients with PA-negative cultures [ Time Frame: Through 6 month follow-up ] [ Designated as safety issue: No ]
To evaluate the proportion of patients with PA-negative microbiological cultures at all time points during a 6 month monitoring period (through Day 196) after cessation of 28 day course of AZLI.
Complete list of historical versions of study NCT01375049 on ClinicalTrials.gov Archive Site
  • Change From Baseline in FEV1% Predicted [ Time Frame: Baseline to Days 28, 56, 112, and 196 ] [ Designated as safety issue: No ]
    Spirometry assessments were performed only in participants ≥ 6 years of age. Forced expiratory volume in 1 second (FEV1) % predicted was defined as FEV1 of the participant divided by the average FEV1 in the population for any person of similar age, sex and body composition.
  • Change From Baseline in CFQ-R RSS Score [ Time Frame: Baseline to Days 28, 56, 112, and 196 ] [ Designated as safety issue: No ]
    Respiratory symptoms (eg, coughing, congestion, wheezing) were assessed with the Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Symptoms Scale (RSS) only in participants ≥ 6 years of age. The range of scores (units) is 0 to 100 with higher scores indicating fewer symptoms.
  • Percentage of Participants With PA-negative Cultures [ Time Frame: Days 28, 56, 112, and 196 ] [ Designated as safety issue: No ]
    The percentage of participants with a PA-negative culture was summarized at each visit.
  • Use of Additional (Non-study) Antipseudomonal Antibiotics [ Time Frame: Baseline to Day 196 ] [ Designated as safety issue: No ]
    The percentage of participants who used additional (non-study) antipseudomonal antibiotics (an indication of PA exacerbation) while on treatment and posttreatment was summarized.
  • Change From Baseline in Weight [ Time Frame: Baseline to Days 28, 56, 112, and 196 ] [ Designated as safety issue: No ]
  • Change From Baseline in Height [ Time Frame: Baseline to Days 28, 56, 112, and 196 ] [ Designated as safety issue: No ]
  • Change From Baseline in Body Mass Index (BMI) [ Time Frame: Baseline to Days 28, 56, 112, and 196 ] [ Designated as safety issue: No ]
  • Pharmacokinetics (PK) Peak and Trough Plasma Concentrations of Aztreonam [ Time Frame: Day 1 (1 hour postdose) and Day 28 (immediately prior to dosing) ] [ Designated as safety issue: No ]
    The plasma concentration of aztreonam for participants < 6 years of age was obtained 1 hour after the first dose of AZLI on Day 1 and immediately prior to the last dose of AZLI on Day 28.
Not Provided
Not Provided
Not Provided
 
Aztreonam Lysine for Pseudomonas Infection Eradication Study
Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients With Cystic Fibrosis (CF) and New Onset Lower Respiratory Tract Culture Positive for Pseudomonas Aeruginosa (PA)

This is an open-label, multi-center study in pediatric patients age 3 months to less than 18 years with cystic fibrosis (CF) and newly detected Pseudomonas aeruginosa (PA) pulmonary colonization/infection. All eligible participants will be treated with a 28-day course of Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily. After completion of study drug, subjects will be followed up through Day 196 for safety and recurrence of PA.

The primary objective is to evaluate the proportion of participants with PA-negative cultures at all time points during a 6-month monitoring period (through Day 196) after cessation of AZLI treatment. Microbiological cultures will be obtained at Baseline, Day 28 (end of AZLI treatment), Day 56 (1 month after completing AZLI treatment), Day 112 (3 months after completing AZLI treatment), and Day 196 (6 months after completing AZLI treatment).

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Cystic Fibrosis
Drug: Aztreonam for Inhalation Solution (AZLI)
AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
Other Name: Cayston®
Experimental: Aztreonam for Inhalation Solution (AZLI)
Participants will receive one 28-day course of AZLI, then will be followed for a 24-week period (through Day 196).
Intervention: Drug: Aztreonam for Inhalation Solution (AZLI)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
105
May 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males or females age 3 months to less than 18 years
  • Diagnosis of CF as determined by the 1997 CF Consensus Conference criteria:

    • Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test OR
    • Abnormal nasal transepithelial potential difference test OR
    • Two well-characterized, disease-causing genetic mutations in the CF transmembrane conductance regulator (CFTR) gene AND
    • One or more clinical features consistent with CF
  • Documented new onset of positive lower respiratory tract culture (e.g., throat swab, sputum, or BAL) for PA within 30 days of study entry (prior to screening visit) defined as either first lifetime documented PA-positive culture OR PA recovered after at least a 2 year history of PA-negative respiratory cultures (at least 2 cultures per year)
  • Forced expiratory volume in 1 second (FEV1) ≥ 80% predicted at screening visit (subjects ≥ 6 years of age)
  • Clinically stable with no evidence of significant respiratory symptoms or, if obtained for clinical evaluation, no chest radiograph findings at screening that would have required administration of IV antipseudomonal antibiotics, oxygen supplementation, or hospitalization.
  • All sexually active females who were of childbearing potential must agree to use a highly effective method of contraception during heterosexual intercourse throughout the study. Females utilizing hormonal contraceptives as a birth control method must have used the same method for at least 3 months prior to study drug dosing.
  • Males must agree to use barrier contraception (condom with spermicide) during heterosexual intercourse from screening through to study completion and for 90 days from the last dose of study investigational medicinal product
  • Participants and/or parent/guardian must be able to give written informed consent prior to any study related procedure

Exclusion Criteria:

  • Use of IV or inhaled antipseudomonal antibiotics within 2 years of study entry (screening visit)
  • Use of oral antipseudomonal antibiotics within 30 days of study entry (screening visit)
  • History of sputum or throat swab culture yielding Burkholderia spp. within 2 years prior to screening visit
  • History of local or systemic hypersensitivity to monobactam antibiotics
  • History of intolerance to inhaled short acting beta 2 agonists
  • History of lung transplantation
  • History of AZLI (or Cayston®) administration
  • Administration of any investigational drug or device within 28 days prior to screening visit or within 6 half-lives of the investigational drug (whichever is longer)
  • Current use of oral corticosteroids in doses exceeding the equivalent of 10 mg prednisone per day or 20 mg prednisone every other day
  • Current requirement for daily continuous oxygen supplementation or requirement of more than 2 L/minute at night
  • Hospitalization for pulmonary-related illness within 28 days prior to screening visit
  • Changes in or initiation of chronic azithromycin treatment within 28 days prior to screening visit
  • Changes in antimicrobial, bronchodilator (BD), corticosteroid, dornase alfa, or hypertonic saline medications within 7 days prior to screening visit; for participants on a stable regimen of hypertonic saline (28 days on/28 days off), beginning or ending a cycle of hypertonic saline is allowed
  • Changes in physiotherapy technique or schedule within 7 days prior to screening visit
  • Abnormal renal or hepatic function results at most recent test within the previous 12 months, defined as:

    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times upper limit of normal (ULN), or
    • Serum creatinine > 2 times ULN for age
  • Pregnant or lactating females; a negative urine pregnancy test is required for all females of childbearing potential (unless surgically sterile), and confirmatory serum pregnancy test in the event of an initial positive urine test result
  • Any serious or active medical or psychiatric illness (including drug or alcohol abuse), which in the opinion of the investigator, would interfere with treatment, assessment, or compliance with the protocol
  • Presence of a condition or abnormality that would compromise the patient's safety or the quality of study data, in the opinion of the investigator
Both
3 Months to 17 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Italy,   France,   Germany,   Netherlands,   Spain,   Belgium,   Poland,   Austria
 
NCT01375049
GS-US-205-0162
Yes
Gilead Sciences
Gilead Sciences
Not Provided
Study Director: Mark Bresnik, MD Gilead Sciences
Gilead Sciences
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP